Why tirzepatide isn't working for you — and what actually explains it

The myth: "Tirzepatide just doesn't work for me"

This is the most common framing, and it's usually the wrong one. Tirzepatide (sold in the UK as Mounjaro) is a dual GIP and GLP-1 receptor agonist, the only medicine of its kind licensed here for weight management. In the SURMOUNT-1 trial, published in the New England Journal of Medicine, participants at the 15mg dose lost an average of around 20–21% of their body weight over 72 weeks. That's a large, well-evidenced effect. The medicine works. What varies enormously between individuals is when and how much.

The starter dose (2.5mg) exists to settle your system before any meaningful therapeutic effect kicks in. Expecting visible weight loss at that level is like expecting a car to accelerate before the engine has warmed up. Most people who report that tirzepatide "doesn't work" are still in the early titration phase, haven't yet reached a maintenance dose, or have encountered a temporary plateau that feels permanent but isn't.

That said, there are genuine reasons progress can stall, and they're worth understanding clearly, because most are addressable.

Dose, timing and the titration curve

The time it takes tirzepatide to work is longer than most people expect. Titration typically moves in four-week steps: 2.5mg, then 5mg, 7.5mg, and upward to the dose where appetite suppression becomes clinically meaningful for you. Some people respond strongly at 5mg; others need to reach 10mg or higher before the effect on hunger and food intake is noticeable day to day.

Adherence matters too. A missed injection (especially on a weekly schedule) doesn't just remove that dose; it can briefly reset the steady-state level in your system, blunting the effect around it. The Mounjaro patient information covers what to do if a dose is missed, but the practical takeaway is that consistency matters more than most people realise.

Injection technique and site rotation also play a role. Injecting repeatedly into scar tissue or an area with poor circulation can reduce absorption. The abdomen, thigh and upper arm are the licensed sites; rotating between them, as described in the Patient Information Leaflet on the eMC, keeps absorption consistent.

If you're wondering whether you've reached the right dose or whether your titration schedule makes sense, that's a question for your prescriber, not something to adjust independently.

Why a plateau isn't the same as failure

Hitting a period where the scales don't move is genuinely frustrating. It's worth knowing it's also physiologically normal. As body weight falls, your resting metabolic rate adjusts downward; the caloric deficit that produced loss early in treatment becomes smaller over time, and progress slows. This happens on every weight-loss intervention, not just tirzepatide.

The medicine is still working during a plateau, it's still suppressing appetite, slowing gastric emptying, and supporting the metabolic changes that protect against regain. The question is whether the surrounding conditions are still supporting further loss. Sleep quality, stress levels, protein intake, and physical activity all affect the trajectory. None of these override biology, but they do modulate it.

Some people also find that gastrointestinal side effects earlier in treatment led them to eat less consistently or differently, and that habits formed then have become the new baseline, sometimes helpful, sometimes not. If you're unsure why Mounjaro doesn't seem to be working despite being on a stable dose, a review of those factors with a prescriber is the most productive next step. For context on what tirzepatide typically costs as part of a private treatment programme, the Mounjaro pricing page sets that out.

When it genuinely might not be the right fit, and what to do

There are real clinical scenarios where tirzepatide is less effective or where a different approach may be warranted. Certain medications interact with GLP-1 medicines. Some medical conditions affect the response. If you've been on a stable, well-tolerated maintenance dose for six months or more and weight loss has been minimal, that's the point at which your prescriber should formally review whether continuing makes sense, the NICE appraisal of tirzepatide (TA1026) recommends reviewing treatment if less than 5% weight loss has occurred after six months at the highest tolerated dose.

It's also worth being honest with yourself about what "not working" means. If you expected the numbers on the SURMOUNT-1 graph to apply to your first three months, that's a calibration issue rather than a treatment failure. If you've been fully adherent, on an appropriate dose for the right duration, with reasonable lifestyle support, and genuinely seen nothing, that's a different conversation, and one worth having directly with a clinician.

You can explore your options and talk to a prescriber through nume's free consultation, where a GPhC-registered Independent Prescriber reviews your case the same day. If you're already on treatment elsewhere and wondering whether something has changed, the related question of why tirzepatide may have stopped working covers the mid-treatment picture in more detail. Our FAQs address some of the most common concerns about treatment response too.